U.S. markets open in 7 hours 22 minutes
  • S&P Futures

    4,618.00
    +28.00 (+0.61%)
     
  • Dow Futures

    35,400.00
    +188.00 (+0.53%)
     
  • Nasdaq Futures

    15,956.00
    +113.25 (+0.71%)
     
  • Russell 2000 Futures

    2,223.40
    +19.80 (+0.90%)
     
  • Crude Oil

    70.37
    +0.88 (+1.27%)
     
  • Gold

    1,783.30
    +3.80 (+0.21%)
     
  • Silver

    22.44
    +0.18 (+0.82%)
     
  • EUR/USD

    1.1296
    +0.0009 (+0.08%)
     
  • 10-Yr Bond

    1.4340
    0.0000 (0.00%)
     
  • Vix

    27.18
    -3.49 (-11.38%)
     
  • GBP/USD

    1.3280
    +0.0019 (+0.14%)
     
  • USD/JPY

    113.7200
    +0.2300 (+0.20%)
     
  • BTC-USD

    51,316.59
    +3,129.23 (+6.49%)
     
  • CMC Crypto 200

    1,325.75
    +65.60 (+5.21%)
     
  • FTSE 100

    7,232.28
    +109.96 (+1.54%)
     
  • Nikkei 225

    28,455.60
    +528.23 (+1.89%)
     

SI-BONE To Report Third Quarter 2021 Financial Results on November 8, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SANTA CLARA, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2021 after market close on Monday, November 8, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by dialing (866) 470-1968 for domestic callers or (409) 217-8248 for international callers, using conference ID: 4991983. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. In 2009, SI-BONE introduced the iFuse Implant System for minimally invasive surgery of the SI joint, shown to be a source of pain in 15% to 30% of chronic low back pain. Since then, more than 2,500 surgeons have performed a combined total of more than 60,000 SI joint fusion procedures. A unique body of evidence, supporting the iFuse Implant System, including two RCT’s and over 100 peer reviewed publications, has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System. SI-BONE is leveraging its market leadership position, supported by this proprietary reimbursement advantage, to commercialize other devices intended for surgical treatment of related aspects of the human anatomy. For more information or to join our team, please visit us at www.si-bone.com.

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2021 SI-BONE, Inc. All Rights Reserved.

Investor Contact:

Matt Bacso, CFA
investors@SI-BONE.com

Media Contact:
Joe Powers
jpowers@si-bone.com